Tempest Therapeutics, Inc. 8-K

What Happened

• Tempest Therapeutics, Inc. (TPST) filed an 8‑K on Jan 9, 2026 disclosing that Nasdaq’s Listing Qualifications Department notified the company on Jan 8, 2026 that it is not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold an annual meeting within 12 months of its fiscal year end of Dec 31, 2024.
• The company has scheduled its 2025 Annual Meeting for Jan 27, 2026; holding that meeting will restore compliance with the Nasdaq annual meeting requirement.

Key Details

• Nasdaq letter received: January 8, 2026.
• Annual meeting scheduled: January 27, 2026.
• Cure period: 45 calendar days from Jan 8, 2026 (until Feb 23, 2026) to regain compliance or submit a plan.
• If Nasdaq accepts a plan, it may grant an exception through June 29, 2026 (up to 180 days from the fiscal year end).

Why It Matters

• This is a formal Nasdaq compliance notice; if Tempest does not regain compliance or Nasdaq rejects any remediation plan, Nasdaq could begin delisting proceedings.
• The company’s scheduled meeting (Jan 27, 2026) is the stated remedy and, if held, will bring TPST back into compliance. Investors should watch filings and announcements for confirmation the meeting occurred and for any Nasdaq responses or further notices.